Balamenib - Eilean Therapeutics
Alternative Names: ZE-630302Latest Information Update: 17 Sep 2024
Price :
$50 *
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 13 Jun 2024 Pharmacodynamics and adverse events data from preclinical studies in Acute myeloid leukaemia presented at the 29th Congress of the European Haematology Association
- 13 Mar 2024 Phase-I clinical trials in Acute myeloid leukaemia (In volunteers) in Australia (PO)
- 11 Mar 2024 Eilean Therapeutics receives clearance from Australian Therapeutics Goods Administration to initiate a phase I trial of balamenib